OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

By News Health
4 hours Ago

(MedPage Today) — BERLIN — Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, according to results from…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118023

Author :

Publish date : 2025-10-19 19:55:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

'Remarkable' Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

'It Could Be Cheap, but It Still Could Be Poison': What We Heard This Week

Could Thymic Health Predict Immunotherapy Outcomes?

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis

Checkpoint Blockade Finally Breaks Through in Ovarian Cancer